This paper reviews the studies that have examined piracetam, the first of the nootropic drugs, as a treatment for developmental reading disorder. In various studies, 751 children have completed treatment in controlled double-blind trials using standardised tests of reading as outcome measures. Quantitative and qualitative review suggests that the findings are best interpreted as showing a statistical superiority of piracetam over placebo. Mechanism of action and clinical significance are discussed. The effect size is modest, but the drug is well tolerated and the balance of benefit over hazard is encouraging for future use.
Keywords: Clinical Significance; Piracetam; Placebo; Qualitative Review; Standardise Test.
Piracetam and Dyslexia: Effects on Reading TestsCR Wilsher et al. J Clin Psychopharmacol 7 (4), 230-7. PMID 3305591. - Clinical TrialPrevious research has suggested that dyslexics treated with piracetam have shown improvements in reading skills, verbal memory and verbal conceptualizing ability, feature …
The Nootropic Concept and DyslexiaCR Wilsher. Ann Dyslexia 36 (1), 118-37. PMID 24243455.A review is presented of controlled studies using intensive teaching intervention to improve dyslexics' reading ability. The results of eight controlled studies reveal on …
Piracetam Prevents Cognitive Decline in Coronary Artery Bypass: A Randomized Trial Versus PlaceboI Szalma et al. Ann Thorac Surg 82 (4), 1430-5. PMID 16996947. - Randomized Controlled TrialSix weeks after CABG, cognition was significantly improved in patients treated with piracetam. Additional trials are required to confirm these effects.
The Role of Piracetam in the Treatment of Acute and Chronic AphasiaW Huber. Pharmacopsychiatry 32 Suppl 1, 38-43. PMID 10338107. - ReviewPiracetam has been shown to improve speech in aphasic patients. This paper reviews the evidence for this benefit in aphasic patients with acute stroke and, in conjunction …
Piracetam and Piracetam-Like Drugs: From Basic Science to Novel Clinical Applications to CNS DisordersAG Malykh et al. Drugs 70 (3), 287-312. PMID 20166767. - ReviewThere is an increasing interest in nootropic drugs for the treatment of CNS disorders. Since the last meta-analysis of the clinical efficacy of piracetam, more informatio …